Navigation Links
Researcher, magnet lab receive $2 million grant to target tuberculosis
Date:1/17/2008

TALLAHASSEE, Fla. -- About 5,000 people around the world die from tuberculosis every day, but no effective new drugs have been developed to combat it in 40 years. Researchers at the National High Magnetic Field Laboratory at Florida State University hope to change that through research made possible by a $2-million grant from the National Institutes of Health.

The award will make it possible for Timothy A. Cross, the Earl Frieden Professor of Chemistry and Biochemistry at FSU, and his team to work toward arming drug developers with a map of the proteins on the bacterias surface that are vital for infection.

Because it isnt often seen in the news in the United States, TB often is overlooked, but it remains one of the globes most deadly infectious diseases. The bacterial infection primarily attacks the lungs, causing 2 million deaths around the world each year. Many of the worlds poor are among its victims, and researchers have raised the alarm about drug-resistant strains of the infection, which, according to the Centers for Disease Control, now account for almost one in five new TB cases.

Some potential new treatments for TB already are being researched, said Cross, who also directs the magnet labs Nuclear Magnetic Resonance program, but there is no knowing if those treatments will survive clinical trials.

Trying to treat so much of the world with the same pharmaceuticals is one of the best ways to develop more resistance to treatment, so its important to come at this from as many angles as possible, he said.

Weve done a preliminary study that shows our work is viable, and we have a lot of preliminary data, Cross said of the research plan, expected to take five years to execute. His team, collaborating with the University of Kansas, the University of Alabama and Case Western Reserve University, will use the magnet labs sophisticated 900 megahertz magnet, as well as other resources, to conduct its research.

Cross thinks the eventual development of a new family of TB drugs could attack the disease in a new and more effective way. He explained that a specific set of proteins appears to be important to TBs ability to attack the body. His team will identify the target proteins that allow bacteria to infect lung tissue. When a drug binds to one of these proteins, it can render the protein ineffective, shutting down its ability to do harm.

We ought to be able to solve the molecular structure of these drug targets, he said. If you know the shape of the protein, then you can design a drug that can bind to it specifically. Getting detailed information about the correct drug target makes it far easier for the pharmaceutical companies to develop safer, more effective treatment.

There has been a lot of interest in our proposal, Cross said, adding, The quality of the graduate students here at FSU made the difference for us. Without a quality research team like this one, this project goes nowhere and our chance of funding work this important would have been zero.


'/>"/>

Contact: Timothy A. Cross
cross@magnet.fsu.edu
850-644-0917
Florida State University
Source:Eurekalert  

Related medicine news :

1. Society of Cardiovascular Magnetic Resonance chooses open access
2. Transcranial magnetic stimulation: An effective treatment for depression
3. Penn research shows transcranial magnetic stimulation effective in treating major depression
4. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
5. A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging
6. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
7. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
8. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
9. Novadaqs SPY System receives clearance for use in organ transplant surgery
10. Philadelphia Policeman Helps Amputee Receive Power Wheelchair from The Scooter Store
11. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher, magnet lab receive $2 million grant to target tuberculosis
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of ... was inspired to practice medicine at an early age by his father, who was ... diagnoses and prescribing medicine,” he states. “It is about building relationships with people; relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report losing ... report speaking with their child about sex related topics, less than 60 percent spoke ... proud to announce the launch of its second edition of the “Sexual Wellness” campaign, ...
(Date:12/2/2016)... ... 02, 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory ... CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of their ... version is a faster and a more efficient product, allowing batch processing of ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- UCB is pleased to announce that 12 scientific abstracts have ... American Epilepsy Society (AES) Annual Meeting, which takes place ... USA. 1-12 Data being presented include ... ® (lacosamide) CV and BRIVIACT ® (brivaracetam) CV. ... state of the union of epilepsy care and antiepileptic drugs ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 Research and ... Intracranial Pressure Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... brain and the skull. In healthy individuals, it is circulated though the ... are cases where the amount of CSF surrounding the brain changes significantly. ...
Breaking Medicine Technology: